Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Doctors' Understanding of Survival Statistics (MPIB)

This study has been completed.
Sponsor:
Collaborator:
Dartmouth-Hitchcock Medical Center
Information provided by:
Max Planck Institute for Human Development
ClinicalTrials.gov Identifier:
NCT00981019
First received: September 18, 2009
Last updated: July 20, 2011
Last verified: July 2011
  Purpose

The probably most commonly used measure for expressing the pay-offs of early detection and treatment are survival rates. Yet, over time and groups this metric comes with several biases and thus, is not reliable for judging such benefits. Epidemiologists recommend using reduction of disease-specific mortality rates instead, which is unbiased. The purpose of the study is to investigate how primary care physicians understand and use different survival measures for determining the benefit of cancer screening tests.


Condition
Screening

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: Study of Primary Care Physicians' Understanding and Use of Different Survival Measures

Further study details as provided by Max Planck Institute for Human Development:

Primary Outcome Measures:
  • Number of Physicians (=Participants) Recommending the Screening [ Time Frame: 25 minutes (mean duration of the survey) ] [ Designated as safety issue: No ]
    The aim of the study was to learn how different medical cancer screening statistics would influence doctors' recommendation behavior and their effectiveness judgments of screening tests. For that reason the online survey study presented physicians with four different medical statistics (e.g., 5-year survival) within four successive scenarios and asked after each scenario whether they would recommend the screening to a (hypothetical) patient given the data. Options to answer are: Definitely yes, Probably yes, Probably no, Definitely no, Can't decide.


Secondary Outcome Measures:
  • Number of Physicians (= Participants) Assuming a Benefit of Screening [ Time Frame: 25 minutes (mean duration of the survey) ] [ Designated as safety issue: No ]
    Physicians are faced with four different medical statistics about the effect of screening (e.g., 5-year survival) within four successive scenarios and after each scenario asked whether they assume the screening to be beneficial given the statistical information. Options to answer are: yes, no, can't decide. If yes, then participants are further asked to describe this benefit by the following categories: Very large, large, moderate, small, very small.


Enrollment: 778
Study Start Date: December 2009
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
mortality*incidence*5-year survival*early stage
Physicians will be faced in scenarios about screening with information on mortality and 5-year survival, followed by information on mortality*incidence and 5-year survival*early stage in a random order.

  Eligibility

Ages Eligible for Study:   30 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

301 primary care physicians (internal, general, and family medicine physicians)

Criteria

Inclusion Criteria:

  • primary care physicians (internal, general, and family medicine physicians)

Exclusion Criteria:

  • all other types of physicians
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00981019

Locations
Germany
Max Planck Institute for Human Development
Berlin, Germany, 14195
Sponsors and Collaborators
Max Planck Institute for Human Development
Dartmouth-Hitchcock Medical Center
Investigators
Principal Investigator: Odette Wegwarth, Dr. Max Planck Institute for Human Development
  More Information

Additional Information:
No publications provided by Max Planck Institute for Human Development

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr. Odette Wegwarth, Max Planck Institute for Human Development/ Harding Center for Risk Literacy
ClinicalTrials.gov Identifier: NCT00981019     History of Changes
Other Study ID Numbers: MPIB-01-SM
Study First Received: September 18, 2009
Results First Received: May 20, 2011
Last Updated: July 20, 2011
Health Authority: Germany: Ethics Commission

Keywords provided by Max Planck Institute for Human Development:
survival rates
risk communication
screening counselling
screening recommendation
understanding of medical risk

ClinicalTrials.gov processed this record on November 25, 2014